INVION LIMITED — Investor Presentation 2012

Sep 9, 2012

ASX / MEDIA ANNOUNCEMENT

10 September 2012

INVION TO BE INTRODUCED AT RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE

Australian drug development company Invion Limited (ASX:IVX) is pleased to announce that Managing Director and Chief Executive Officer Dr William Garner is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference on September 9-11, 2012, at the Waldorf Astoria hotel in New York, NY.

Dr Garner will be introducing Invion to a wide range of industry and investment professionals, describing the company’s vision, development plan and forthcoming milestones for its programs in the area of inflammatory and autoimmune diseases, including chronic bronchitis, asthma, smoking cessation and lupus.

The Invion presentation is scheduled for Tuesday, September 11, 2012 at 4.45pm (EDT).

About Invion Limited

Invion Limited is a clinical-stage drug development company that targets chronic inflammation. Focussed on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus, Invion has two phase II proprietary therapeutic candidates: INV102 – a repurposed inverse beta agonist; and Cpn10 – a modified natural immunomodulator. INV102, also known as nadolol, has been used in more than 8 million people for the treatment of high blood pressure, migraine and chest pain. Invion is now targeting INV102 for new indications. To date, two phase II clinical trials of INV102 have been completed which have demonstrated acceptable safety as well as dose-related activity showing a reduction of airway hyper-responsiveness. Two further phase II trials are due to commence in 2H 2012. The larger of these trials, a phase II $4.4 million study in asthma patients, is being funded by the US National Institutes of Health (NIH). Cpn10 is a potential new anti-inflammatory biologic therapeutic. In clinical trials carried out to date, Cpn10 has demonstrated clear signs of biological activity, including a reduction in disease-relevant pro-inflammatory cytokines. Invion is progressing regulatory preparations to investigate Cpn10 as a treatment for systemic lupus erythematosus (SLE or lupus). Invion’s pre-Investigational New Drug (pre-IND) meeting with the US Food and Drug Administration (FDA) is scheduled for 14 December 2012.

FOR MORE INFORMATION CONTACT:

CorporateDr William GarnerManaging Director and CEOInvion Limitedinvestor@invion.com.au	Investor RelationsRebecca WilsonBuchan Consulting03 9866 4722rwilson@buchanwe.com.au	MediaTom DonovanBuchan Consulting(03) 9866 4722tdonovan@buchanwe.com.au